tiprankstipranks
Avrobio upgraded to Buy from Neutral at BTIG
The Fly

Avrobio upgraded to Buy from Neutral at BTIG

BTIG analyst Yun Zhong upgraded Avrobio to Buy from Neutral with a $4 price target. This morning’s update, from four Gaucher disease type 1 patients that received AVR-RD-02 treatment in the ongoing Phase 1/2 Guard1 study and one type 3 patient treated on named-patient basis in the UK, support the company’s lentiviral gene therapy programs’ promising potential in lysosomal storage disorders, according to the analyst. The Gaucher data, although still from a limited number of patients and after modest follow-up periods, "still justify the re-inclusion of the program into valuation" and, hence, the upgrade to Buy.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on AVRO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles